You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. HHSN261201400048C; TOPIC 309??DEVEL.OF.LOW COST,SMALLSAMPLE MULTI-ANAL.TECH.FORCANCER DIAGNOSIS,PROGNOSISandEARLY DETECTION?;TITLE: DEPLOYMENT.OF.PROTOTYPE SYSTEM FOR DETECTION OF MULTI. ANAL. IN SMAL

    SBC: ENUMERAL BIOMEDICAL CORPORATION            Topic: NCI

    Not Available

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  2. IGF::OT::IGF SBIR PHASE II TOPIC 308 IMAGE BASED MOBILE SYSTEM FOR DIETARY ASSESSMENT AND COACHING

    SBC: Vignet Inc.            Topic: NCI

    Not Available

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. IGF::OT::IGF SBIR Phase II Topic 62, Strategy for Finding Cases of Moderate-to-Severe COPD

    SBC: DIMAGI, INC.            Topic: DLD

    Not Available

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. IGF::OT::IGF SBIR Topic 58, Phase II- High-Voltage Li-ion Battery for Left Ventricular Assist Device Power

    SBC: GINER INC            Topic: NHLBI

    Not Available

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Praedicare Dx as CDx for AML Period of Performance: September 19, 2014 through September 18, 2015

    SBC: Eutropics Pharmaceuticals, Inc.            Topic: DCCPS

    Not Available

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Advancing a Mucosal HSV-2 Vaccine Towards Clinical Trials

    SBC: Biomedical Research Models, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Globally, an estimated 16.2% of the human population is infected with HSV-2 including gt17% of the U.S. adult population. Genital herpes is associated with an increased risk of HIV acquisition and transmission and HSV-2infection can cause neonatal herpes with high infant mortality. HSV-2 infection in the adult population has increased substantially in the past ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Portable Gas Perfusion System for Pancreas Preservation

    SBC: GINER INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Pancreatic islet transplantation (ITx) is an emerging treatment for a subset of Type 1 diabetics for which standard insulin therapies are insufficient. I is a promising alternative to pancreas transplantation, since ITxhas significantly less surgical risk and a less toxic immunosuppression regimen. Enhanced organ preservation via the proposed technology has the ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Transforming Dialysis into a Controlled Drug Delivery System for Stem Cell Derive

    SBC: Sentien Biotechnologies, Inc.            Topic: NIDDK

    DESCRIPTION (provided by applicant): The goal of this Phase IIB SBIR application is to test the Sentien cellular bioreactor product (the Sentinel ) in a first-in-man study to assess safety and preliminary efficacy. Fifteen post-cardiac surgery patients that are diagnosed with acute kidney injury and indicated for dialysis will be enrolled and connected to the Sentinel containing one of three escal ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. PDGFR and KDR Inhibitors for Liver Fibrosis

    SBC: Angion Biomedica Corp.            Topic: NIDDK

    ? DESCRIPTION (provided by applicant): The incidence and prevalence of both alcoholic and non-alcoholic liver diseases is increasing. The population presenting with Metabolic Syndrome, a key risk factor for NAFLD-NASH-liver fibrosis is ballooning. Leftuntreated, liver fibrosis can progress to cirrhosis or end-stage liver disease and even hepatocellular carcinoma. Today, therapeutic strategies ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. A potassium-ATP channel opener for prevention of contrast-induced nephropathy

    SBC: RADIKAL THERAPEUTICS, INC.            Topic: NIDDK

    Contrast media (CM) induced nephropathy (CIN) remains prevalent and debilitating, the third most common cause of acute renal failure. Based on more than 80 million (M) CM injections in the USA per annum, of which 10% take place in a population highly susceptible to the development of CIN, and a unit pricing of 200 per course, we estimate the total domestic potential market equals 1.6B. At presen ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government